In order to implement the requirements of “carrying out skills training around professional inspector team construction” of leading Party group of the CFDA, to promote the capacity of inspectorate, and constantly improve the professional skills and comprehensive quality of the inspectors, the 2nd Experts’ Forum of CFDI was held successfully according to the work plan of CFDI Academic Committee on March, 31,2017. The academician, Liu Changxiao from the Tianjin Institute of pharmaceutical research, was invited in this expert forum, he made a lecture entitled “National drug safety strategy and biomedical development situation”.
Academician Liu Changxiao, as one of the pioneers and academic leaders of pharmacokinetics in China, has long been committed to the research of new drugs, and has undertaken and participated in major research projects such as 863,973 national and provincial research projects, and gained great research achievements. In this lecture, he analyzed the risks and measures of China’s medicine safety in details, and comprehensively introduced the situation and development trends of China's bio-pharmaceutical industry and supervision policy from the strategic perspective of national security. His lecture is based on a high point of view, a wide range of vision, a comprehensive content, large amounts of information, with the basis of both a detailed statistical data, but also integrated with years of in-depth research and strategic thinking.
More than 70 fellows from CFDI, the Chinese Pharmacopoeia Commission, Beijing Drug Certification Management Center, Beijing Medical Device Technology Review Center attended the lecture. A number of 13 provincial drug inspection institutes in the whole country conducted synchronous watching through the video system.
After listening to the lecture, the participants expressed that in the study of relevant knowledge, they not only understood the overall situation of China's pharmaceutical industry, enhanced the confidence toward the development of China's pharmaceutical industry, but also strengthened the crisis and risk awareness of national drug safety, furthermore, enhanced the responsibility for protection of people's drug safety.
